|Oral and Injectables
|Hospitals, Ambulatory Surgical Centers, Clinics, and Others
|North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|2023 - 2031
Consegic Business Intelligence analyzes that the opioid anesthetics market is growing with a CAGR of 4.4% during the forecast period (2023-2031). The market accounted for USD 805.00 million in 2022 and USD 839.36 million in 2023, and the market is projected to be valued at USD 1,188.06 Million by 2031.
Opioid anesthetics are drugs that are used in conjunction with local and general anesthesia to enhance the effectiveness of the anesthesia, improve its delivery and reduce the required dosage. These drugs are administered perineurally along with local anesthetics to extend the duration of anesthesia without increasing the risk of adverse effects. Opioids are widely used in the practice of anesthesia, as primary anesthetics, for pre-anesthetic medication, supplementation of general anesthetic agents. The efficient use of opioid anesthetics is done by careful titration of dose as per the individual patient's response to the drug and to noxious stimulation. A wide range of opioid anesthetics such as morphine, fentanyl, sufentanyl, hydromorphone, buprenorphine and tramadol are commonly used for this purpose.
Adjuvants are medications that are administered together with local or general anesthetics to increase their effectiveness, improve delivery, or decrease the required dosage. These medications work together with local anesthetics to enhance the duration and quality of anesthesia in regional techniques. Over time, the range of local anesthetic adjuvants has expanded from classical opioids to a broad variety of drugs with varying mechanisms of action, all aimed at improving the anesthetic experience. These drugs are used for better management of pain and anesthesia during surgeries. Additionally, the rise the surgeries is propelling the use of adjuvant anaesthesia drugs. For instance, according to the data published on NCBI on July 29, 2020, globally, a staggering 310 million major surgeries are performed each year; around 40 to 50 million in the USA and 20 million in Europe.
The rise in the number of surgeries is fuelling the demand for opioid anaesthetics. Opioid anesthetics are used in combination with local and general anesthetic drugs to increase the effectiveness of drug and prevent pain during surgical procedures like dental surgeries, cardiac surgeries, cosmetic surgeries, breast cancer biopsies, bone fractures, knee replacement, and cataract removal. These anesthetics are widely used as pre-anesthesia medications, adjuvant anesthetic medications, and post-operation medications. They are especially vital in treating pain and as anesthesia adjuncts or primary anesthetic agents during surgery and postoperatively. Additionally, the rising number of surgeries is boosting the market for opioid anesthetics globally. For instance, according to the report published by American Society of Plastic Surgeons in September 2023, cosmetic surgery procedures have grown by 19% in 2022 compared to 2019. Furthermore, in June 2021, Canadian Health Information Institute report showed that 55,300 hip replacements and 55,285 knee replacements were performed in Canada during 2020-2021.
Opioids are a key tool in anesthesia and surgical pain management. However, opioids come with a range of potential side effects, including respiratory depression, exacerbation of obstructive sleep apnea, post-operative nausea, vomiting, ileus, hyperalgesia (increased sensitivity to pain), drowsiness, delirium, hypotension, urinary retention, and risk of tolerance. These side effects can range from mild to severe depending upon the resistance and acceptance capacity of person to person. According to the report published by the Centers for Disease Control and Prevention in December 2022, the rate of drug overdose deaths involving synthetic opioids other than methadone increased by 22% in 2021. Moreover, approval of opioid-based drugs requires a strict regulatory framework and guidelines by the regulatory agencies which further extends the approval time for opioid-based anesthetic drugs. Thus, the complex regulatory processes along with the side effects of opioid drugs significantly hamper the opioid anesthetic market.
The prevalence of chronic disorders is rising globally. There is a significant growth observed in the pharmaceutical and healthcare sectors post-COVID-19 pandemic. Additionally, advancement in the healthcare infrastructure and government initiatives for better management of health is expected to fuel the market for opioid anesthetics for surgical treatment. For instance, according to the data published by the India Brand Equity Foundation in August 2023, in the Union Budget 2023-24, the Indian government allocated USD 10.76 billion to the Ministry of Health and Family Welfare (MoHFW). Moreover, the increasing number of hospitals in the developing countries is expected to potentially fuel the market. For instance, according to the report by Investment Information and Credit Rating Agency, in August 2023, the hospital sector is driving a robust revenue growth of 8-10% in FY24, with an operating profit margin at 22-23%. This will boost the distribution of cancer drugs in the hospital pharmacies.
|Market Size in 2031
|USD 1,188.06 Million
|Oral and Injectables
|Hospitals, Ambulatory Surgical Centers, Clinics, and Others
|North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
|Hikma Pharmaceuticals, Pfizer Inc., Merck & Co., Grünenthal, AcelRx Pharmaceuticals, Inc., AbbVie Inc., Viatris Inc., Novalab Healthcare, Piramal Critical Care
The type segment is categorized into oral and injectables. In 2022, the injectable segment accounted for the highest market share in the overall opioid anesthetics market, and it is expected to grow at the fastest CAGR in the overall opioid anesthetics market. Several injectable opioid anesthetics are typically administered intravenously, transdermally, and subcutaneously in the body during surgical operations. Most of the anesthetic drugs are available in injectable form, leading to the dominance of this segment. Additionally, Intravenous administration of drugs increases the bioavailability of the drug and improves patient safety. Thus, the advantages related to injectable drugs is driving the segment globally.
The end-users segment is categorized into hospitals, ambulatory surgical centers, clinics, and others. In 2022, the hospital segment accounted for the highest market share of 56.75% in the overall opioid anesthetics market. Hospitals are outfitted with a comprehensive suite of healthcare facilities, encompassing an array of medical instruments, devices, diagnostic laboratories, and pharmacies that are essential for surgical procedures. These facilities are designed to provide patients with optimal care and support throughout the surgical process. The healthcare professionals who operate surgeries are highly trained and skilled in their respective areas of expertise, ensuring that patients receive the utmost care and attention from start to finish. Moreover, the rise in the hospital sector is significantly driving the segment. For instance, according to the report by Investment Information and Credit Rating Agency, in August 2023, the hospital sector is driving a robust revenue growth of 8-10% in FY24, with an operating profit margin at 22-23%.
However, the ambulatory surgical centers segment is expected to grow at the fastest CAGR in the overall opioid anesthetics market. Ambulatory surgery centers, or ASCs, are modern healthcare facilities focused on providing same-day emergency surgical care, including diagnostic and preventive procedures, avoiding hospital admissions. Moreover, the surgical solutions provided by ambulatory surgical centers are cost- effective. Hence, it is expected to bring lucrative growth in ambulatory surgical centers segment.
The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Regional Growth InsightsDownload Sample Report
In 2022, North America accounted for the highest market share at 37.30% valued at USD 300.27 Million in 2022 and USD 313.42 Million in 2023, it is expected to reach USD 444.93 Million in 2031, and it is also the fastest growing region across the globe, growing with a CAGR of 4.8% over the forecast period. In the North America region, the U.S. accounted for the highest market share of 65.55% during the base year 2022, owing to the increasing geriatric population, advanced healthcare facilities and services, increase in chronic disorders surgeries, and significant growth in the pharmaceutical and healthcare industry. Additionally, the growing pharmaceutical research and development is substantially driving the market in the region. For instance, according to the report by the National Center for Science and Engineering Statistics in September 2023, in financial year (FY) 2022, the 42 federally funded research and development centers (FFRDCs) in the United States spent USD 26.5 billion on research and development (R&D). This was a 6.4% increase from the previous year.
Details Countries Growth InsightsDownload Sample Report
The opioid anesthetics market is highly competitive, with several large players and numerous small and medium-sized enterprises. These companies have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships. The key players in the market include-
In 2022, the market size of opioid anesthetics was USD 805.00 million.
In 2031, the market size of opioid anesthetics will be expected to reach USD 1,188.06 million.
Rising use of adjuvant anesthesia drugs is propelling the opioid anesthetics market growth.
In 2022, the hospitals segment accounted for the highest market share of 56.75% in the overall Opioid Anesthetics market.
North America is expected to be the fastest-growing region in the market during the forecast period.